Biotech Stocks to Watch for Monday; (OTCBB: UVFT),(NASDAQ:CLRT), (AMEX: PIP) , (NASDAQ: VRNM)
Biotech Investors see wins for the week of 15-39% on top gainers
Point Roberts, WA –October 24, 2010 (Investorideas.com Newswire and www.biotechindustrystocks.com) - InvestorIdeas.com, a leader in sector research tools for investors, reports on Biotech/ Pharma Stocks recent news and trading.
Biotech Stocks to follow Monday based on Friday’s volume and gains as well as last week’s include UV Flu Technologies, Inc., (OTCBB: UVFT), Clarient, Inc. (NASDAQ: CLRT), PharmAthene, Inc. (AMEX:PIP) and Verenium (NGM:VRNM).
Last weeks biotech stock leaders included Clarient, NASDAQ: CLRT), Verenium (NGM:VRNM). (Pharmathene (AMEX:PIP), Aryx Therapeutics (ARYX) and Labopharm (DDS) . Biotech investors trading these stocks last week saw gains of 15- 39%.
Sector Snapshot: (Trading at Market close Friday October 22)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $0.35, up 0.03 (9.37%)
Clarient, Inc. (NASDAQ:CLRT), trading at $ 4.97, up 1.2350 (33.02%) on 50,532,499 volume of shares
PharmAthene, Inc. (AMEX:PIP) trading at $3.85, -0.04 (-1.03%)
Verenium Corporation (Nasdaq: VRNM) trading at $4.00 USD, up 0.18 (4.71%)
Biotech Stocks on the Move
UV Flu Technologies, Inc., (OTCBB: UVFT) Stock up 9.37% on the day
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
UV Flu Technologies Inc., already has FDA Approval as a Class II Medical Device making the company ahead of its competitors and a Biotech Stock to watch
View latest research report at http://www.biotechstockpick.com/
Latest News:
Biotechnology Stock News; UV Flu Technologies (OTCBB: UVFT) Reports Boston Bruins Now a Customer for ViraTech UV-400 Air Purifying Units
“UV Flu Technologies, Inc. (OTCBB: UVFT) reports that Massachusetts based distributor, New England Sports Sales (“NESSI”), a national distributor of hockey and related equipment to college and professional hockey teams across the USA and Canada, has recently placed an order of ViraTech UV-400 air purifying units in the locker room of the renowned Boston Bruins hockey team.
Full Article: http://finance.yahoo.com/news/UV-Flu-Technologies-Adds-iw-2297079947.html?x=0&.v=1
Website: http://www.uvflutech.com/ and www.biotechstockpick.com
Recent Research
Research Report Excerpt; Key Highlights on UVFT.OB –
Written by Michael Williams at http://biotechstockpick.com/. Michael Williams is America’s top authority on small-cap biotech stock picks.
10 reasons to invest in UVFT
…for what could be the killer biotech buy of the year with 370% profit potential!
1. FDA approval has already been received, allowing UVFT to market its product as a medical device—such approval is highly unusual for a biotech at this stage. Not to mention very few air purifiers have FDA approval. That gives UVFT a big competitive edge.
2. Top 5 U.S. Hospitals Put UVFT Technology to Work—UVFT’s UV-400 is already in operation at two of the most respected medical institutions: The Division of Infectious Diseases at Massachusetts General Hospital and New England Baptist Hospital.
3. Independent laboratory testing proves UVFT’s technology works and is 99.2% to 99.9% effective at killing bacteria on the first pass.
4. OSHA, the main U.S. federal agency charged with the enforcement of safety and health legislation, is creating a moneymaking opportunity for UVFT and its shareholders. Indoor air quality is a growing problem, creating health hazards and sick buildings. OSHA is already issuing directives to provide a healthier work environment for workers.
5. This year’s bad flu season is all it will take to send UVFT’s share price soaring to potential highs of 370% or higher. Business and consumers are going to want the best protection available—and it won’t be blue masks.
6. Strong buyout potential by corporate giants 3M or Honeywell that could send share prices through the rafters.
7. Shares at the ground floor entry point of just $0.30— this is the stage you stand to make the biggest gains—this low price still has blue sky potential.
8. Experienced management team—a powerhouse team that’s been with the heavyweights in health care and finance—those such as Johnson and Johnson and Janney Montgomery Scott. One key team member already successfully brought a $20 million per year product to market! Now UVFT is about to do it again. see pg. 10
9. THREE revenue streams already in place: the flagship Viratech UV-400, the smaller version of the UV-400, and replaceable cartridges for the units are all avenues for UVFT to generate a steady revenue stream.
10. UVFT has the first breakthrough in the air purification market in 70 years. Breakthroughs like that create investment opportunities of a lifetime.
Clarient, Inc. (NASDAQ:CLRT) Recent News: Stock up 33% on the day
“Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/clrt) is investigating potential claims against the board of directors of Clarient, Inc. ("Clarient" or the "Company") (NASDAQ:CLRT - News) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million.”
Full Article: http://finance.yahoo.com/news/Ryan-Maniskas-LLP-Announces-bw-3775341173.html?x=0
Verenium Corporation (Nasdaq: VRNM) recent news –
The shares rose $1.13 or 34.8 percent to $4.38 Wednesday on this news
Verenium Announces Regulatory Approval for Purifine® PLC in China
CAMBRIDGE, Mass., Oct. 20 Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance enzyme solutions, today announced that Purifine® PLC, the Company's novel enzyme specifically developed for the edible oil industry, has received all necessary Chinese government authorizations for sale as a processing aid in the edible oil industry. With this regulatory approval, Verenium now has the ability to sell Purifine® PLC in all the major oilseed processing areas of the world, which include Argentina, Brazil, the United States and China.
Full news – see company website http://www.verenium.com/.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
About our Biotech investor portal:
www.BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech and pharma sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory Biotech Companies - become a biotech showcase stock on www.investorideas.com and www.biotechindustrystocks.com for as little as $1000 month !
Showing posts with label (OTCBB: UVFT). Show all posts
Showing posts with label (OTCBB: UVFT). Show all posts
Sunday, October 24, 2010
Wednesday, September 29, 2010
Investorideas.com - UV Flu Technologies Receives Large UV-400 Air Purifier Order Directly Targeting Residential Marketplace
Investorideas.com - UV Flu Technologies Receives Large UV-400 Air Purifier Order Directly Targeting Residential Marketplace
OTCBB:UVFT
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - September 29, 2010 (http://www.investorideas.com/ newswire, http://www.biotechindustrystocks.com/) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company has received an order for 100 UV-400 air purifying units from Semper Fi, a Long Island based distribution company which primarily markets to residential consumers.
The Distributor has advised that they are actively adding representatives to cover sales leads encompassing the Tri-State area. In response, the Company has ensured that an ample quantity of units to satisfy initial sales needs have been priority diverted for immediate shipment to the client.
"This order is significant because our product was principally designed for the commercial marketplace," said Jack Lennon, President of UV Fu Technologies. "Our UV-400 has been laboratory tested and proven to offer highly effective airborne bacteria-killing capabilities that will provide Semper Fi with a product truly superior to anything else currently in the marketplace."
Mr. Lennon continues, "We want to also note that in the residential market we have received feedback from the field where certain individuals have reported a dramatic difference in their respiratory issues in as little as 2-3 hours from starting their UV-400 at home. In the past month alone, we have received testimonials from consumers indicating that individuals with sleep disorders due to snoring have seen significant improvement while operating the unit in their bedroom at night. The Company makes no claims in this area, but is planning to follow up on these reports in order to determine if further study or future development in this area is warranted."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.bout UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
OTCBB:UVFT
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - September 29, 2010 (http://www.investorideas.com/ newswire, http://www.biotechindustrystocks.com/) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that the company has received an order for 100 UV-400 air purifying units from Semper Fi, a Long Island based distribution company which primarily markets to residential consumers.
The Distributor has advised that they are actively adding representatives to cover sales leads encompassing the Tri-State area. In response, the Company has ensured that an ample quantity of units to satisfy initial sales needs have been priority diverted for immediate shipment to the client.
"This order is significant because our product was principally designed for the commercial marketplace," said Jack Lennon, President of UV Fu Technologies. "Our UV-400 has been laboratory tested and proven to offer highly effective airborne bacteria-killing capabilities that will provide Semper Fi with a product truly superior to anything else currently in the marketplace."
Mr. Lennon continues, "We want to also note that in the residential market we have received feedback from the field where certain individuals have reported a dramatic difference in their respiratory issues in as little as 2-3 hours from starting their UV-400 at home. In the past month alone, we have received testimonials from consumers indicating that individuals with sleep disorders due to snoring have seen significant improvement while operating the unit in their bedroom at night. The Company makes no claims in this area, but is planning to follow up on these reports in order to determine if further study or future development in this area is warranted."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.bout UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838investors@uvflutech.com
SOURCE: UV Flu Technologies, Inc.
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Subscribe to:
Posts (Atom)